Scarica l'app Stockscreener
75.78
0.40%
0.30
Precedente Chiudi:
$75.48
Aprire:
$75.96
Volume 24 ore:
943.19K
Relative Volume:
1.11
Capitalizzazione di mercato:
$5.18B
Reddito:
-
Utile/perdita netta:
$-146.66M
Rapporto P/E:
-27.52
EPS:
-2.7541
Flusso di cassa netto:
$-133.21M
1 W Prestazione:
-1.99%
1M Prestazione:
+9.62%
6M Prestazione:
+70.98%
1 anno Prestazione:
+60.72%
Intervallo 1D:
$73.54
$76.07
Intervallo di 1 settimana:
$73.54
$78.34
Portata 52W:
$26.20
$80.99
Apogee Therapeutics Inc Stock (APGE) Company Profile
Nome
Apogee Therapeutics Inc
Settore
Industria
Telefono
650-394-5230
Indirizzo
221 CRESCENT ST., WALTHAM
Confronta APGE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
75.78 | 5.16B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-17 | Iniziato | Stephens | Overweight |
| 2025-12-10 | Iniziato | Deutsche Bank | Buy |
| 2025-11-03 | Iniziato | Craig Hallum | Buy |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-09-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-07-07 | Reiterato | BTIG Research | Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2024-11-25 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-10 | Iniziato | BofA Securities | Buy |
| 2023-12-20 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | Guggenheim | Buy |
| 2023-08-08 | Iniziato | Jefferies | Buy |
| 2023-08-08 | Iniziato | Stifel | Buy |
| 2023-08-08 | Iniziato | TD Cowen | Outperform |
| 2023-08-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Apogee Therapeutics Inc Borsa (APGE) Ultime notizie
Has Rana Sugars Limited Stock Bottomed Out Recovery Potential ReviewedMarket Capitalization Trends & Reduce Losses With Smart Exit Strategies - earlytimes.in
Apogee Therapeutics Inc. (NASDAQ:APGE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Apogee Therapeutics Inc (NASDAQ:APGE) Nasdaq today Early Biotech Stage - Kalkine Media
Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
BTIG reiterates Buy rating on Apogee Therapeutics stock amid positive outlook - Investing.com
Value Recap: What technical signals suggest for Apogee Therapeutics Inc. stockMarket Activity Report & Safe Entry Zone Identification - moha.gov.vn
Apogee Therapeutics Earnings Notes - Trefis
Henderson, Apogee Therapeutics CFO, sells $120k in stock - Investing.com
Apogee Therapeutics CFO Sells 1,500 Shares - TradingView — Track All Markets
Will Apogee Therapeutics Inc. stock benefit from AI adoption2025 Winners & Losers & Weekly Top Performers Watchlists - Улправда
Apogee Therapeutics (APGE) Gets a Buy from Bank of America Securities - The Globe and Mail
Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug - MSN
Apogee Therapeutics stock hits all-time high of 78.19 USD - Investing.com
Apogee Therapeutics stock hits all-time high of 78.19 USD By Investing.com - Investing.com Nigeria
Apogee Therapeutics (NASDAQ:APGE) Hits New 12-Month HighWhat's Next? - MarketBeat
Is Apogee Therapeutics Inc. stock a safe investment in uncertain markets2025 Winners & Losers & Safe Capital Growth Tips - DonanımHaber
Apogee Therapeutics (NASDAQ:APGE) Rating Increased to Strong-Buy at Stephens - MarketBeat
Market Outlook: Will Apogee Therapeutics Inc. stock benefit from AI adoptionWeekly Market Summary & Weekly Return Optimization Alerts - ulpravda.ru
Will Apogee Therapeutics Inc. stock gain from lower inflation2025 Buyback Activity & Smart Investment Allocation Insights - Улправда
Trend Recap: What insider trading reveals about Apogee Therapeutics Inc. stockMarket Movers & Fast Exit and Entry Strategy Plans - Улправда
What insider trading reveals about Apogee Therapeutics Inc. stockQuarterly Trade Summary & Technical Analysis for Trade Confirmation - Улправда
What dividend safety score for Apogee Therapeutics Inc. stockWeekly Trade Report & Risk Managed Investment Entry Signals - ulpravda.ru
How Apogee Therapeutics Inc. stock benefits from global expansionMarket Risk Summary & Daily Stock Trend Reports - Улправда
Stephens Initiates Coverage on Apogee Therapeutics With Overweight Rating, $95 Price Target - marketscreener.com
Stephens & Co. initiates coverage of Apogee Therapeutics (APGE) with overweight recommendation - MSN
How Apogee Therapeutics Inc. (APGE) Affects Rotational Strategy Timing - Stock Traders Daily
Michael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock - MarketBeat
Apogee Therapeutics Inc. $APGE Shares Sold by Braidwell LP - MarketBeat
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics CEO Sells 20,000 Shares - TradingView — Track All Markets
CEO Henderson Sells 20,000 ($1.5M) Of Apogee Therapeutics Inc [APGE] - TradingView — Track All Markets
Apogee Therapeutics (NASDAQ:APGE) Hits New 1-Year HighHere's Why - MarketBeat
Apogee Therapeutics stock reaches all-time high of 77.21 USD - Investing.com India
Apogee Therapeutics stock reaches all-time high of 77.21 USD By Investing.com - Investing.com Canada
Stempoint Capital LP Makes New Investment in Apogee Therapeutics Inc. $APGE - MarketBeat
Deutsche Bank Initiates Apogee Therapeutics at Buy With $103 Price Target - marketscreener.com
Deutsche Bank Initiates Coverage of Apogee Therapeutics (APGE) with Buy Recommendation - Nasdaq
Apogee Therapeutics initiated with a buy at Deutsche Bank - MSN
Apogee Therapeutics stock initiated with Buy rating at Deutsche Bank By Investing.com - Investing.com South Africa
Apogee Therapeutics stock initiated with Buy rating at Deutsche Bank - Investing.com
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Manila Times
Strong Pipeline and Analyst Confidence Push Apogee Therapeutics Inc. (APGE) Toward Growth - Yahoo Finance
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Certain Restricted Stock Units of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-DEC-2025. - marketscreener.com
Certain Stock Options of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-DEC-2025. - marketscreener.com
Apogee Therapeutics (NASDAQ:APGE) CEO Sells $3,000,400.00 in Stock - MarketBeat
Carl Dambkowski Sells 10,900 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock - MarketBeat
Schroder Investment Management Group Boosts Stock Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Apogee Therapeutics CMO sells $817k in stock By Investing.com - Investing.com Australia
Insider Sell: Jane Henderson Sells 1,500 Shares of Apogee Therap - GuruFocus
Apogee Therapeutics Inc Azioni (APGE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apogee Therapeutics Inc Azioni (APGE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Henderson Jane | Chief Financial Officer |
Dec 19 '25 |
Sale |
80.00 |
1,500 |
120,000 |
193,371 |
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):